Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat

British Journal of Pharmacology

Volumn 142, Issue 7, 2004, Pages 1171-1181

  Storer, Robin James ^a   Akerman, Simon ^a   Goadsby, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CGRP antagonist; Cluster headache; Headache; Migraine; Trigeminocervical complex

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE[8-37]; GLUTAMIC ACID; N [2 [[5 AMINO 1 [[4 (4 PYRIDINYL) 1 PIPERAZINYL]CARBONYL]PENTYL]AMINO] 1 [(3,5 DIBROMO 4 HYDROXYPHENYL)METHYL] 2 OXOETHYL] 4 (1,4 DIHYDRO 2 OXO 3 (2H) QUINAZOLINYL) 1 PIPERIDINECARBOXAMIDE; OLCEGEPANT; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INNERVATION; CELL ACTIVATION; CONTROLLED STUDY; CRANIOTOMY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ELECTROSTIMULATION; FACE; LAMINECTOMY; MICROIONTOPHORESIS; MIGRAINE; NERVE CELL STIMULATION; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTIVE FIELD; RECORDING; SKIN STIMULATION; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NERVE;

ACTION POTENTIALS; ANIMALS; BRAIN; CALCITONIN GENE-RELATED PEPTIDE; CATS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; IONTOPHORESIS; PEPTIDE FRAGMENTS; PIPERAZINES; QUINAZOLINES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; RECEPTORS, PRESYNAPTIC; SYNAPTIC TRANSMISSION; TIME FACTORS; TRIGEMINAL CAUDAL NUCLEUS; TRIGEMINAL NUCLEI;

EID: 4143102442     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705807     Document Type: Article

References (78)

1. AKERMAN, S., WILLTAMSON, D.J., KAUBE, H. & GOADSBY, P.J. (2002). Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol., 137, 62-68.
2. ARMITAGE, P & BERRY, G (1994). Statistical Methods in Medical Research, 3rd edn. Oxford: Blackwell Science.
3. BAHRA, A., MATHARU, M.S., BUCHEL, C., FRACKOWIAK, R.S.J. & GOADSBY, P.J. (2001). Brainstem activation specific to migraine headache. Lancet, 357, 1016-1017.
4. BEREITER, D.A., BEREITER, D.F. & HATHAWAY, C.B. (1996). The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomie responses to corneal stimulation in the rat. Pain, 64, 179-189.
5. BLOOM, F.E. (1974). To spritz or not to spritz: the doubtful value of aimless iontophoresis. Life Sci., 14, 1819-1834.
6. CARLTON, S.M., HARGETT, G.L. & COGGESHALL, R.E. (2001). Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. Neuroscience, 105, 957-969.
7. CHOKSI, T., HAY, D.L., LEGON, S., POYNER, D.R., HAGER, S., BLOOM, S.R. & SMITH, D.M. (2002). Comparison of the expression of caicitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br. J. Pharmacol., 136, 784-792.
8. COLLIN, E., FRECHILLA, D., POHL, M., BOURGOIN, S., LE BARS, D., HAMON, M. & CESSELIN, F. (1993). Opioid control of the release of caicitonin gene-related peptide-like material from the rat spinal cord in vivo. Brain Res., 609, 211-222.
9. CUMBERBATCH, M.J., HILL, R.G. & HARGREAVES, R.J. (1997). Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol., 328, 37-40.
10. CUTRER, F.M., LIMMROTH, V., AYATA, G. & MOSKOWITZ, M.A. (1995). Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br. J. Pharmacol., 116, 3199-3204.
11. + pump α2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet., 33, 192-196.
12. DE VRIES, P., VILLALON, C.M. & SAXENA, P.R. (1999). Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol., 375, 61-74.
13. DENNIS, T., FOURNIER, A., CADIEUX, A., POMERLEAU, F., JOLICOEUR, F.B., ST. PIERRE, S. & QUIRION, R. (1990). hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther., 254, 123-128.
14. DOODS, H., HALLERMAYER, G., WU, D., ENTZEROTH, M., RUDOLF, K., ENGEL, W. & EBERLEIN, W. (2000). Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol., 129, 420-423.
15. EDVINSSON, L., EKMAN, R., JANSEN, I., McCULLOCH, J. & UDDMAN, R. (1987). Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J. Cereb. Blood Flow Metabol., 7, 720-728.
16. EDVINSSON, L. & GOADSBY, P.J. (1998). Neuropeptides in headache. Eur. J. Neurol., 5, 329-341.
17. EKBOM, K. & THE SUMATRIPTAN CLUSTER HEADACHE STUDY GROUP (1991). Treatment of acute cluster headache with sumatriptan. N. Engl. J. Med., 325, 322-326.
18. FANCIULLACCI, M., ALESSANDRI, M., FIGINI, M., GEPPETTI, P. & MICHELACCI, S. (1995). Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain, 60, 119-123.
19. FEINDEL, W., PENFIELD, W. & McNAUGHTON, F. (1960). The tentorial nerves and localization of intracranial pain in man. Neurology, 10, 555-563.
20. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 358, 1668-1675.
21. FRIBERG, L., OLESEN, J., IVERSEN, H.K. & SPERLING, B. (1991). Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet, 338, 13-17.
22. FUSSEY, I.F., KIDD, C. & WHITWAM, J.G. (1970). The differentiation of axonal and soma-dendritic spike activity. Pflugers Arch., 321, 283-292.
23. GALLAI, V., SARCHIELLI, P., FLORIDI, A., FRANCESCHINI, M., CODINI, M., TREQUATTRINI, A. & PALUMBO, R. (1995). Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia, 15, 384-390.
24. GOADSBY, P.J. (1993). Inhibition of calcitonin gene-related peptide by h-CGRP(8-37) antagonizes the cerebral dilator response from nasociliary nerve stimulation in the cat. Neurosci. Lett., 151, 13-16.
25. GOADSBY, P.J. (2000). The pharmacology of headache. Prog. Neurobiol., 62, 509-525.
26. 1) receptors in the trigeminocervical complex. Ann. Neurol., 50, 804-807.
27. GOADSBY, P.J. & EDVINSSON, L. (1993). The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol., 33, 48-56.
28. GOADSBY, P.J. & EDVINSSON, L. (1994a). Human in vivo evidence for trigeminovascular activation in cluster headache. Brain, 117, 427-434.
29. GOADSBY, P.J. & EDVINSSON, L. (1994b). Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache, 34, 394-399.
30. GOADSBY, P.J., EDVINSSON, L. & EKMAN, R. (1988). Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol., 23, 193-196.
31. GOADSBY, P.J., EDVINSSON, L. & EKMAN, R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol., 28, 183-187.
32. 1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain, 67, 355-359.
33. GOADSBY, P.J. & HOSKIN, K.L. (1997). The distribution of trigeminovascular afferents in the nonhuman primate brain Macaco nemestrina: a c-fos immunocytochemical study. J. Anat., 190, 367-375.
34. GOADSBY, P.J. & LAMBERT, G.A. (1986). An interactive, readily transportable program using a log/logit transformation for the analysis of radioimmunoassay data. Comput. Methods Programs Biomed., 23, 263-268.
35. GOADSBY, P.J., LIPTON, R.B. & FERRARI, M.D. (2002). Migraine-current understanding and treatment. N. Engl. J. Med., 346, 257-270.
36. GOADSBY, P.J. & ZAGAMI, A.S. (1991). Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain, 114, 1001-1011.
37. HELLIER, M., BOERS, P. & LAMBERT, G.A. (1990). Fabrication of a metal-cored multi-barrelled rnicroiontophoresis assembly. J. Neurosci. Meth., 32, 55-61.
38. HILL, R.G. & SALT, T.E. (1982). An iontophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. J. Physiol., 327, 65-78.
39. 1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp. Neurol., 150, 45-51.
40. HOSKIN, K.L. & GOADSBY, P.J. (1999). Exposure and isolation of the superior sagittal sinus elicits Fos in the trigeminal nucleus caudalis and dorsal horn of the cervical spinal cord: how long should you wait? Brain Res., 824, 133-135.
41. HOSKIN, K.L., KAUBE, H. & GOADSBY, P.J. (1996). Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain, 119, 249-256.
42. HOSKIN, K.L., ZAGAMI, A. & GOADSBY, P.J. (1999). Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. J. Anat., 194, 579-588.
43. 1D receptors in the human trigeminal ganglion: co-localization with calitonin gene-related peptide. substance P and nitric oxide synthase. Brain Res., 909, 112-120.
44. HU, J.W., DOSTROVSKY, J.O. & SESSLE, B.J. (1981). Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn). I. Responses to oral-facial noxious and nonnoxious stimuli and projections to thalamus and subnucleus oralis. J. Neurophysiol., 45, 173-192.
45. KAUBE, H., HOSKIN, K.L. & GOADSBY, P.J. (1993a). Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol., 109, 788-792.
46. KAUBE, H., KEAY, K.A., HOSKIN, K.L., BANDLER, R. & GOADSBY, P.J. (1993b). Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical cord following stimulation of the superior sagittal sinus in the cat. Brain Res., 629, 95-102.
47. LIMMROTH, V., MAY, A., AUERBACH, P., WOSNITZA, G., EPPE, T. & DIENER, H.C. (1996). Changes in cerebral blood now velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J. Neurol. Sci., 138, 60-65.
48. 1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur. J. Neurosci., 13, 2099-2104.
49. MANDELBROD, I., FELDMAN, S. & WERMAN, R. (1974). Inhibition of firing is the primary effect of microelectrophoresis of cortisol to units in the rat tuberal hypothalamus. Brain Res., 80, 303-315.
50. MANDELBROD, I., FELDMAN, S. & WERMAN, R. (1983). Mediobasal hypothalamic neurons are excited by the iontophoretic application of sodium. Brain Res., 273, 35-44.
51. MATHARU, M., BARTSCH, T., WARD, N., FRACKOWIAK, R., WEINER, R. & GOADSBY, P. (2003). Central neuromodulation with implanted suboccipital stimulators in patients with chronic migraine. Cephalalgia, 23, 655.
52. MAY, A., BAHRA, A., BUCHEL, C., FRACKOWIAK, R.S.J. & GOADSBY, P.J. (1998). Hypothalamic activation in cluster headache attacks. Lancet, 352, 275-278.
53. McLATCHIE, L.M., FRASER, N.J., MAIN, M.J., WISE, A., BROWN, J., THOMPSON, N., SOLARI, R., LEE, M.G. & FOORD, S.M. (1998). RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 393, 333-339.
54. MITSIKOSTAS, D.D., SANCHEZ del RIO, M., WAEBER, C., HUANG, Z., CUTRER, F.M. & MOSKOWITZ, M.A. (1999). Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br. J. Pharmacol., 127, 623-630.
55. MITSIKOSTAS, D.D., SANCHEZ del RIO, M., WAEBER, C., MOSKOWITZ, M.A. & CUTRER, F.M. (1998). The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain, 76, 239-248.
56. MORENO, M.J., ABOUNADER, R., HÉBERT, E., DOODS, H. & HAMEL, E. (2002). Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology, 42, 568-576.
57. MOSKOWITZ, M.A. & CUTRER, F.M. (1993). SUMATRIPTAN: a receptor-targeted treatment for migraine. Ann. Rev. Med., 44, 145-154.
58. NAGLER, J., CONFORTI, N. & FELDMAN, S. (1973). Alterations produced by cortisol in the spontaneous activity and responsiveness to sensory stimuli of single cells in the tuberal hypothalamus of the rat. Neuroendocrinology, 12, 52-66.
59. OLESEN, J. (1991). Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. Cerebrovasc. Brain Metab. Rev., 3, 1-28.
60. OLESEN, J., DIENER, H.-C., HUSSTEDT, I.W., GOADSBY, P.J., HALL, D., MEIER, U., POLLENTIER, S. & LESKO, L.M. (2003). Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. Cephalalgia, 23, 579.
61. OLESEN, J., FRIBERG, L., SKYHOJ-OLSEN, T., IVERSEN, H.K., LASSEN, N.A., ANDERSEN, A.R. & KARLE, A. (1990). Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol., 28, 791-798.
62. 2+ channel gene CACNL1A4. Cell, 87, 543-552.
63. PANNETON, W.M. & BURTON, H. (1981). Corneal and periocular representation within the trigeminal sensory complex in the cat studied with transganglionic transport of horseradish peroxidase. J. Comp. Neurol., 199, 327-344.
64. PETERSEN, K.A., BIRK, S., LASSEN, L.H., KRUUSE, C., JONASSEN, O. & OLESEN, J. (2003a). The novel CGRP-antagonist, BIBN4096BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia, 23, 729.
65. PETERSEN, K.A., LASSEN, L.H., BIRK, S. & OLESEN, J. (2003b). The effect of the nonpeptide CGRP-antagonist, BIBN406BS on human-alphaCGRP induced headache and hemodynamics in healthy volunteers. Cephalalgia, 23, 725.
66. POWELL, K.J., MA, W., SUTAK, M., DOODS, H., QUIRION, R. & JHAMANDAS, K. (2000). Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol., 131, 875-884.
67. SALT, T.E. & HILL, R.G. (1982). Differentiation of excitatory amino acid receptors in the rat caudal trigeminal nucleus: a microiontophoretic study. Neuropharmacology, 21, 385-390.
68. 1B/1D) agonist doses. Neuropharmacology, 40, 911-917.
69. STORER, R.J., AKERMAN, S. & GOADSBY, P.J. (2001b). GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br. J. Pharmacol., 134, 896-904.
70. STORER, R.J., BUTLER, P., HOSKIN, K.L. & GOADSBY, P.J. (1997). A simple method, using 2-hydroxypropyl-β-cyclodextrin, of administering α-chloralose at room temperature. J. Neurosci. Meth., 77, 49-53.
71. 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain, 120, 2171-2177.
72. STORER, R.J. & GOADSBY, P.J. (1999). Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience, 90, 1371-1376.
73. TALLAKSEN-GREENE, S.J., YOUNG, A.B., PENNEY, J.B. & BEITZ, A.J. (1992). Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci. Lett., 141, 79-83.
74. WAHL, M., SCHILLING, L., PARSONS, A.A. & KAUFMANN, A. (1994). Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res., 637, 204-210.
75. WEILLER, C., MAY, A., LIMMROTH, V., JUPTNER, M., KAUBE, H., SCHAYCK, R.V., COENEN, H.H. & DIENER, H.C. (1995). Brain stem activation in spontaneous human migraine attacks. Nat. Med., 1, 658-660.
76. WILLIAMSON, D.J., HARGREAVES, R.J., HILL, R.G. & SHEPHEARD, S.L. (1997). Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia, 17, 518-524.
77. WOLFF, H.G. (1948). Headache and Other Head Pain. New York: Oxford University Press.
78. YU, L.-C., HANSSON, P. & LUNDEBERG, T. (1996). The calcitonin gene-related peptide antagonist CGRP8-S7 increases the latency to withdrawal responses bilaterally in rats with unilateral experimental mononeuropathy, an effect reversed by naloxone. Neuroscience, 71, 523-531.